BECOME A MEMBER
Connect with healthcare professionals around the globe to get the most up-to-date medical cannabis information.
Get Involved
TAKE OUR COURSES
The curriculum brings hands-on practical guidance on how to develop personalized treatment regimens and more.
Turning Over a New Leaf: Cannabinoid and Endocannabinoid Modulation of Immune Function.
Authors: Guy A. Cabral, Thomas J. Rogers, Aron H. Lichtman
Journal of Neuroimmune Pharmacology, June 2015
—
Cannabis is a complex substance that harbors terpenoid-like compounds referred to as phytocannabinoids. The major psychoactive phytocannabinoid found in cannabis ∆(9)-tetrahydrocannabinol (THC) produces the majority of its pharmacological effects through two cannabinoid recep…
Controlled Cannabis Vaporizer Administration: Blood and Plasma Cannabinoids with and without Alcohol.
Authors: Rebecca L. Hartman, Timothy L. Brown, Gary Milavetz, Andrew Spurgin, et al
Clinical Chemistry, June 2015
—
BACKGROUND: Increased medical and legal cannabis intake is accompanied by greater use of cannabis vaporization and more cases of driving under the influence of cannabis. Although simultaneous Δ(9)-tetrahydrocannabinol (THC) and alcohol use is frequent, potential pharmacokineti…
Use of cannabis in severe childhood epilepsy and child protection considerations.
Authors: Megan Yap, Laura Easterbrook, Jan Connors, Laura Koopmans
Journal of Paediatrics and Child Health, May 2015
—
The use of medical cannabis in chronic illness is increasingly investigated, yet little is known about its use in paediatric populations. As child protection clinicians are often asked to provide advice around whether parents’ actions to give medical cannabis to their chronica…
Use of Prescription Pain Medications Among Medical Cannabis Patients
Authors: Brian E. Perron, Kipling Bohnert, Angela K. Perone, Marcel O. Bonn-Miller, Mark Ilgen
Journal of Studies on Alcohol and Drugs, May 2015
—
OBJECTIVE: Management of chronic pain is one of the most common reasons given by individuals seeking medical cannabis. However, very little information exists about the concurrent use of cannabis and prescription pain medication (PPM). This study fills this gap in knowledge by…
Pure cannabidiol in the treatment of malignant migrating partial seizures in infancy: a case report.
Authors: Dimah Saade, Charuta Joshi
Pediatric Neurology, May 2015
—
BACKGROUND: Malignant migrating partial seizures in infancy is a devastating pharmacoresistent epileptic encephalopathy of unknown etiology characterized by onset in the first 6 months of life, continuous migrating focal seizures with corresponding multifocal electroencephalog…
Research Pioneer: Ethan Russo MD
Ethan Russo, MD, is a board-certified neurologist and psychopharmacology researcher. He has held faculty appointments in Pharmaceutical Sciences at the University of Montana, in Medicine at the University of Washington, and as visiting professor, Chinese Academy of Sciences. He is currently Past-President of the International Cannabinoid Research Society, and is former Chairman of the International Association for Cannabinoid Medicines.
Role of cannabinoid receptor CB2 in HER2 pro-oncogenic signaling in breast cancer.
Authors: Eduardo Pérez-Gómez, Clara Andradas, Sandra Blasco-Benito, María M. Caffarel, et al
Journal of the National Cancer Institute, 8 April 2015
—
BACKGROUND: Pharmacological activation of cannabinoid receptors elicits antitumoral responses in different cancer models. However, the biological role of these receptors in tumor physio-pathology is still unknown. METHODS: We analyzed CB2 cannabinoid receptor protein expressio…
Proapoptotic effect of endocannabinoids in prostate cancer cells.
Authors: O. Orellana-Serradell, C. E. Poblete, C. Sanchez, E. A. Castellón, I. Gallegos, et al
Oncology Reports, April 2015
—
In the early stages, prostate cancer is androgen‑ dependent; therefore, medical castration has shown significant results during the initial stages of this pathology. Despite this early effect, advanced prostate cancer is resilient to such treatment. Recent evidence shows that…
Current Status and Future of Cannabis Research
Authors: Ethan B. Russo, Alice P. Mead, Dustin Sulak
Clinical Researcher, April 2015
—
Although cannabis is primarily viewed by the public as a recreational drug or agent of abuse, its medical application spans recorded history.1,2 Evolution has yielded a cannabis plant that produces a family of some 100 chemicals called phytocannabinoids (“plant cannabinoids”)…
Phytocannabinoids and epilepsy
Authors: R. G. dos Santos, J. E. C. Hallak, J. P. Leite, A. W. Zuardi, J. A. S. Crippa
Journal of Clinical Pharmacy and Therapeutics, April 2015
—
WHAT IS KNOWN AND OBJECTIVE: Antiepileptic drugs often produce serious adverse effects, and many patients do not respond to them properly. Phytocannabinoids produce anticonvulsant effects in preclinical and preliminary human studies, and appear to produce fewer adverse effects…
Cannabinoids in late‐onset Alzheimer’s disease
Authors: AIA Ahmed, MA van der Marck, GAH van den Elsen, MGM Olde Rikkert
Clinical Pharmacology & Therapeutics, 8 March 2015
—
Given the lack of effective treatments for late-onset Alzheimer’s disease (LOAD) and the substantial burden on patients, families, health care systems, and economies, finding an effective therapy is one of the highest medical priorities. The past few years have seen a growing…
Cannabis sativa: the unconventional “weed” allergen.
Authors: Thad L. Ocampo, Tonya S. Rans
Annals of Allergy, Asthma & Immunology, March 2015
—
Passage of legislation in Washington, Colorado, Oregon, Alaska, and the District of Columbia allowing recreational use of marijuana, despite federal regulation to the contrary, highlights the continued debate surrounding this unconventional plant. Allergies to marijuana are no…